is...optimistic for the future of CNS conditions thanks to Anavex Life Sciences.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NVX-CoV2373
This is the week of injections.
https://www.9news.com.au/national/coronavirus-nvxcov2373-vaccine-testing-to-start-in-australia-by-nucleus-network/43f9310c-5ed6-4537-8cf7-e37095bfbff2
Thank you Aussie volunteers!
For optimal dosing via inhalation, I’d go with the Technosphere platform c/o MannKind and United Therapeutics
https://seekingalpha.com/article/4295249-mannkinds-technosphere-platform-issues-are-worth-discussing
Nebulizing Brilacidin would probably be pretty effective though, especially since the mist would go directly into the alveoli where the drug is most needed for treatment in the lungs.
“The Polymedix scientists, DeGrado,Klein,Scott and others who developed Brilacidin will have a shot at the Nobel prize.“
Imagine, after all these years, such recognition on a much-belated accomplishment. Heavy stuff.
Thanks GBA.
Doing searches for phosphodiesterase-4 (PDE4) turns up relevant info
https://www.cochrane.org/CD002309/phosphodiesterase-4-inhibitors-people-chronic-obstructive-pulmonary-disease-copd
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199465/
Really zeroes in on anti inflammatory properties associated with Brilacidin.
That, coupled with existing info regarding ABBSI and Brilacidin’s antimicrobial qualities is a plus.
https://docksci.com/an-independent-evaluation-of-a-novel-peptide-mimetic-brilacidin-pmx30063-for-ocu_5a29cee5d64ab2118322e5e2.html. (old, but good)
Naaaah...
It’s always a pleasure when shorts are forced to contribute to the upward momentum.
Double down on that short position!
Things to consider for Brilacidin...
Likely to become the new standard of care for Oral Mucositis.
Promising results for ABSSSI as well.
Irritable Bowel disease (inflammatory conditions + resistant bacterial infestations) indications are also looking auspicious.
Now it’s being evaluated and advanced along with some other candidates for showing its efficacy in disrupting the wall of the coronavirus. (As if it’s not going to get noticed in the process?! Are you kidding? What big pharma wouldn’t want to add this gem to their collection and reap the rewards?)
Without rehashing all the terminology associated with the aforementioned positives, we’re sitting on a winner. Just a question of when the egg “hatches”.
BETTER SLEEP
Without side effects. Even better. Better functioning at the cellular level!
Defensive-mimetic for the win!
https://en.wikipedia.org/wiki/Defensin" rel="nofollow" target="_blank" >insert-text-here
https://en.wikipedia.org/wiki/Brilacidin" rel="nofollow" target="_blank" >insert-text-here
We’ve got the goods.
Thanks kevli.
Some relevant info (pharmacovigilance)
https://en.wikipedia.org/wiki/Pharmacovigilance" rel="nofollow" target="_blank" >insert-text-here
NVX-CoV2373 (any guesses on future trade name?!)
Novavax is going to crush it.
Not only with NanoFlu, but everything else they have in their pipeline.
Novavax’s breakout would, of course, S.T.E.M. from a pandemic. This is the very thing the company was designed for in the first place.
Consider, in retrospect, this article...
https://journalstar.com/business/investment/markets-and-stocks/is-novavax-inc-a-buy/article_3bda0612-fa59-5618-bb5d-025c127b1772.html" rel="nofollow" target="_blank" >insert-text-here
Now, given the efficacy of NanoFlu (eat it haters), we’re now in the throes of a global pandemic and Novavax has already successfully addressed TWO previous coronaviruses.
Novavax IS the next global leader in vaccination technology.
Lung Delivery Options
1) Nebulizer...inhaled as a diluted solution.
2) Partner with MannKind and utilize the Technosphere technology (dry powder inhalant that goes directly to the lungs’ surfaces.
Either way, it would get where it needs to be to do the most good.
This paragraph is key...
Manufacturing Agreement now in place
https://www.globenewswire.com/news-release/2020/03/31/2009581/0/en/Emergent-BioSolutions-Signs-Agreement-with-Novavax-to-Manufacture-NanoFlu.html" rel="nofollow" target="_blank" >insert-text-here
Trial also achieves statistical significance in key secondary endpoints
Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway
Company to host investor conference call today at 8:30 a.m. EDT
Webcast Conference Call
Novavax will host a webcast/conference call today at 8:30 a.m. ET. The webcast can be accessed via a link on the home page of the Novavax website (novavax.com) or through the “Investor Info”/“Events” tab on the Novavax website. Listeners who wish to ask questions or don’t have internet access can dial-in to the conference call at (877) 212-6076 (domestic) or (707) 287-9331 (international) and use passcode 4498251.
A replay of the webcast will be available on the Novavax website until June 24, 2020 and a replay of the conference call only will be available starting at 11:30 a.m. ET on March 24, 2020 until 11:30 a.m. ET on March 31, 2020. To access the conference call replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and use passcode 4498251.
Fresh publication in Vaccine journal
https://www.mdpi.com/2076-393X/8/1/99
Old, but still good.
https://www.ncbi.nlm.nih.gov/pubmed/24736006
Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.
Coleman CM#1, Liu YV#2, Mu H2, Taylor JK1, Massare M2, Flyer DC2, Smith GE#2, Frieman MB#1.
Author information
Abstract
Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame. The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells. Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.
Just an observation...
Airway (being open) is one of the most critical elements in rendering basic first aid.
Considering that Novavax has positive indications for influenza, respiratory syncytial virus, AND is now working on the coronavirus, ALL associated with afflictions that concern the respiratory tract, it would seem they’re one of the most likely future lifesavers for our species.
Maybe BIIB will offer a 1:1 share agreement to AVXL.
Time will tell.
Nice to see Vanguard increase their stake.
You got this Xena! Hang in there.
Question...
Who could have been in attendance and requesting further information about partnering with Anavex Life Sciences during, or after, the 2020 BIO CEO & Investor Conference?
[url][/url][tag] https://ih.advfn.com/stock-market/NASDAQ/anavex-life-sciences-AVXL/stock-news/81663893/anavex-life-sciences-to-present-and-participate-in[/tag]
Seems like a lot of potential was there.
And special thanks to the moderators.
onus probandi
Best kept secret in the CNS sector.
That would keep the manufacturer(s) busy.
Rett. Alzheimer’s. Parkinson’s. Frontal Temporal Disorder.
Question!
How many other conditions might be addressed with off-label use???
Good times.
Threw 2000 more shares in my Roth IRA on Monday morning.
3-71
Nice to see that 3-71 is now being advanced as well.
“ANAVEX®3-71 successfully completed IND-enabling toxicology studies and drug product manufacturing. ANAVEX®3-71 previously received Orphan Drug Designation from the U.S. FDA for Frontotemporal dementia (FTD). Initiation of the first Phase 1 clinical trial of ANAVEX®3-71 is expected in 2020. ANAVEX®3-71 has demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, inflammation, amyloid and tau pathologies.“
Excellent!
Time to break through that 52 week high and set course for Aldebaran.
STILL looking forward to the time when my vaccines will come from Novavax!
RSV, Influenza, Coronavirus, Ebola, Rabies, et al.
Telling ya’. Disruptive technology for the win!
Levadopa
https://www.ncbi.nlm.nih.gov/books/NBK482140/#_article-23965_s4_
https://www.parkinson.org/Understanding-Parkinsons/Treatment/Prescription-Medications/Levodopa
Pretty funky side effects and contraindications.
Working with China to address their strain.
https://news.bloomberglaw.com/pharma-and-life-sciences/novavax-developing-coronavirus-vaccine-candidate-company-says
LOL. Thanks nidan7500. There are a lot of happenings that are not being covered by press releases. Hopefully there’s a writer documenting these events to craft how everything has come together. It will be an interesting read.
Thanks for the in-depth reply polarbear77.
Plenty of irons in the fire and they’re all glowing.